RTTNews BiotechQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 16:30:42·⟳ 抓取 16:45:25 +14m43s·⚡ 决策 08-26 16:46:57 +1m32s·62.5 天前
Biohaven与SK Biopharmaceuticals就Kv7平台/Opakalim达成全球授权合作（重复消息）
本条RTTNews转述与08-26 06:46 UTC已处理的ir_page一手源记录为同一具体催化（Biohaven-SK Bio Kv7/Opakalim全球授权），交易条款、金额、阶段完全一致，无任何新增金额、指引修正、官方确认/否认或监管进展。已处理记录已给出'值得做'结论，本条不构成重复研判依据。
📄 原文RTTNews Biotech↗ 原文
Biohaven And SK Biopharmaceuticals Enter Strategic Global Licensing Agreement; Stock Up
Biohaven Ltd. (BHVN) and SK Biopharmaceuticals Co., Ltd. announced a global licensing and collaboration agreement for B…
不做 Biohaven（BHVN.US）
同一具体催化（Biohaven-SK Bio Kv7/Opakalim全球授权）已于08-26 06:46 UTC由ir_page一手源处理并判定'值得做'（结论含301760.KS和BHVN.US）。本条RTTNews转述无新增金额、条款、确认或监管进展，属重复消息，不再重复研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RTTNews报道Biohaven与SK Biopharmaceuticals达成Kv7平台全球授权合作，交易总额最高$7.95亿。经跨源检查，同一催化已于约2小时前由Biohaven官方IR页面一手源处理并判定'值得做'（标的BHVN.US和301760.KS）。本条RTTNews转述未带来任何新增事实（金额、条款、阶段、确认均一致），属于同一事件的媒体扩散，不再重复研判。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 medium · price-in 风险 medium ↗
先例如何影响了这次决策
对本次决策的影响:同一催化已由先前处理记录完成研判并给出结论，本条不重复先例研究
工具调用 · 历史记录,结果未知(2 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,953 字
Biohaven Ltd. (BHVN) and SK Biopharmaceuticals Co., Ltd. announced a global licensing and collaboration agreement for Biohaven's Kv7 ion channel platform, led by Opakalim (BHV-7000), a next-generation candidate in development for epilepsy.
Under the terms, SK Biopharmaceuticals will provide upfront and milestone payments of up to $795 million, along with tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of Opakalim.
Opakalim is a selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in the second half of 2026.
Described as a once-daily oral treatment without titration, it aims to reduce burdensome central nervous system side effects often associated with antiseizure medicines.
The agreement combines Biohaven's wholly owned Kv7 platform with SK Biopharmaceuticals' proven epilepsy commercial infrastructure, the same team that launched XCOPRI, an antiseizure drug for partial-onset seizures. This partnership provides Biohaven with non-dilutive capital, strengthens its balance sheet, and extends its runway to advance a differentiated pipeline.
Executives highlighted the potential of Opakalim to deliver meaningful efficacy without sedation or dizziness, positioning it as a novel treatment option for millions of patients with epilepsy if approved.
BHVN has traded between $7.48 and $18.57 over the past year. The stock closed Tuesday's trading at $14.38, up 5.12%. In pre-market trading the stock is at $15.51, up 7.93%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
Under the terms, SK Biopharmaceuticals will provide upfront and milestone payments of up to $795 million, along with tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of Opakalim.
Opakalim is a selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in the second half of 2026.
Described as a once-daily oral treatment without titration, it aims to reduce burdensome central nervous system side effects often associated with antiseizure medicines.
The agreement combines Biohaven's wholly owned Kv7 platform with SK Biopharmaceuticals' proven epilepsy commercial infrastructure, the same team that launched XCOPRI, an antiseizure drug for partial-onset seizures. This partnership provides Biohaven with non-dilutive capital, strengthens its balance sheet, and extends its runway to advance a differentiated pipeline.
Executives highlighted the potential of Opakalim to deliver meaningful efficacy without sedation or dizziness, positioning it as a novel treatment option for millions of patients with epilepsy if approved.
BHVN has traded between $7.48 and $18.57 over the past year. The stock closed Tuesday's trading at $14.38, up 5.12%. In pre-market trading the stock is at $15.51, up 7.93%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。